IBI343 + IBI308

IBI343 + IBI308 refers to a combination of two investigational monoclonal antibody-based therapies developed by Innovent Biologics. **IBI343** is an antibody-drug conjugate (ADC) composed of a recombinant human anti-Claudin 18.2 monoclonal antibody linked to the cytotoxic agent exatecan, a topoisomerase I inhibitor. It specifically targets CLDN18.2-expressing tumor cells, leading to internalization and release of the cytotoxic payload, which induces DNA damage and apoptosis in cancer cells; it also exhibits a "bystander killing effect" on neighboring tumor cells[3][5][6]. The primary indications under investigation for IBI343 are advanced pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and gastric or gastroesophageal junction adenocarcinoma[1][3][5]. **IBI308**, also known as sintilimab, is not described in detail in the provided search results but is widely recognized as an anti-PD-1 monoclonal antibody developed by Innovent Biologics for various cancers.